Inventor · disambiguated record
Nisit Khandelwal
Also filed as: KHANDELWAL NISIT
5 granted patents·14 pending applications·0 citations·filing 2014–2025
62Inventor score
Files withIOMX THERAPEUTICS AG13DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS4DEUTSCHES KREBSFORSCH2
Top patents by PatentIndex Score
19 records- 0171US2025084076A1Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0271US2025101015A1Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0364US11802285B2Cytotoxic T cell response modifiersDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2019·Granted Oct 31, 2023·0 cites·10 claims
- 0464US2025340886A1Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0562US12139480B25-thiazolecarboxamide kinase inhibitor and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Granted Nov 12, 2024·0 cites·18 claims
- 0657US2021379067A1Dasatinib and another 5-thiazolecarboxamide kinase inhibitor, and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 0755US9994854B2Cytotoxic T cell response modifiersDEUTSCHES KREBSFORSCH·Filed 2014·Granted Jun 12, 2018·0 cites·43 claims
- 0851US12172993B2Heterocyclic kinase inhibitors and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Granted Dec 24, 2024·0 cites·53 claims
- 0949US2018298388A1Cytotoxic t cell response modifiersDEUTSCHES KREBSFORSCH·Filed 2018·Application pending·0 cites
- 1048US12338440B2Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2018·Granted Jun 24, 2025·0 cites·33 claims
- 1145US2024010720A1Antibodies binding igv of igsf11 (vsig3) and uses thereofIOMX THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 1244US2023348453A1Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1341US2023228760A1Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1440US2022372138A1Antibodies binding igc2 of igsf11 (vsig3) and uses thereofIOMX THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 1537US2019263906A1Immune modulators for reducing immune-resistance in melanoma and other proliferative diseasesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1636US2020164068A1Modulators of tumor immune resistance for the treatment of cancerDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1735US2020024347A1Or10h1 antigen binding proteins and uses thereofIOMX THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 1833US2019054110A1Modulators of ccr9 for treating tumor resistance to immune responsesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1932US2021061908A1Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Nisit Khandelwal files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →